1. Home
  2. NNNN vs AUPH Comparison

NNNN vs AUPH Comparison

Compare NNNN & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anbio Biotechnology Class A Ordinary Shares

NNNN

Anbio Biotechnology Class A Ordinary Shares

HOLD

Current Price

$21.75

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$13.93

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NNNN
AUPH
Founded
2021
1993
Country
Germany
Canada
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.6B
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
NNNN
AUPH
Price
$21.75
$13.93
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$17.25
AVG Volume (30 Days)
29.0K
937.4K
Earning Date
04-28-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5075.00
EPS
N/A
2.07
Revenue
N/A
$283,055,000.00
Revenue This Year
N/A
$16.53
Revenue Next Year
N/A
$16.24
P/E Ratio
$446.57
$6.78
Revenue Growth
N/A
20.38
52 Week Low
$5.91
$6.83
52 Week High
$55.65
$16.54

Technical Indicators

Market Signals
Indicator
NNNN
AUPH
Relative Strength Index (RSI) 45.15 43.02
Support Level $19.53 $13.52
Resistance Level $30.70 $15.23
Average True Range (ATR) 1.81 0.44
MACD 0.05 -0.03
Stochastic Oscillator 37.28 8.06

Price Performance

Historical Comparison
NNNN
AUPH

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: